Baricitinib in Relapsing Giant Cell Arteritis

Summary

This study will evaluate the safety and effectiveness of baricitinib in the treatment of giant cell arteritis. All participants will be taking prednisone at the start of the study. The prednisone will be reduced according to a standardized tapering schedule while participants continue to take one tablet of baricitinib daily for 52 weeks.

Timeline

Start

2017-03-09

Primary completion

2021-04-12

Completion

2021-04-12

Publications

• Koster MJ, Crowson CS, Giblon RE, Jaquith JM, Duarte-Garcia A, Matteson EL, Weyand CM, Warrington KJ. Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Ann Rheum Dis. 2022 Jun;81(6):861-867. doi: 10.1136/annrheumdis-2021-221961. Epub 2022 Feb 21.

Drugs

Indications